Reviewing 60 Degrees Pharmaceuticals (NASDAQ:SXTP) & Amneal Pharmaceuticals (NASDAQ:AMRX)

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares 60 Degrees Pharmaceuticals and Amneal Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$300,000.00	10.70	-$7.95 million	($3.47)	-0.22
Amneal Pharmaceuticals	$2.79 billion	1.41	-$116.89 million	$0.02	627.75

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

60 Degrees Pharmaceuticals has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for 60 Degrees Pharmaceuticals and Amneal Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1	1	2	0	2.25
Amneal Pharmaceuticals	0	1	4	0	2.80

60 Degrees Pharmaceuticals presently has a consensus price target of $4.40, suggesting a potential upside of 479.71%. Amneal Pharmaceuticals has a consensus price target of $13.50, suggesting a potential upside of 7.53%. Given 60 Degrees Pharmaceuticals’ higher probable upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Institutional & Insider Ownership

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares 60 Degrees Pharmaceuticals and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-616.15%	N/A	-140.98%
Amneal Pharmaceuticals	0.20%	-185.60%	6.20%

Summary

Amneal Pharmaceuticals beats 60 Degrees Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.